<DOC>
	<DOCNO>NCT00743002</DOCNO>
	<brief_summary>This trial design show effect treatment TT223 placebo blood glucose control 12 week treatment 6 month follow-up . TT223 administer injection daily patient currently treat Metformin and/or Thiazolidinedione .</brief_summary>
	<brief_title>A Trial TT223 Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 Diabetes least 6 month Treated metformin and/or thiazolidinediones stable dose least 3 month BMI 2145 kg/m2 , inclusive HbA1c level 7.50 10.00 % , inclusive If female childbearing potential , willing utilize contraception Screening 4 week last dose study drug Treatment insulin , sulfonylurea , DPP4 inhibitor , Symlin® and/or GLP1 analogue ≤ 3 month prior Screening Severe hypoglycemia ≤ 60 day prior Screening visit currently diagnose hypoglycemia unawareness History peptic ulcer ( ) and/or gastrointestinal bleeding/perforation Previous gastric surgery , include gastric bypass , gastric bypass/other major surgery plan occur 10 month trial Myocardial infarction within last 2 year , current congestive heart failure NYHA class 2 great , chronic atrial fibrillation Current clinically significant and/or chronic illness Takes regular course nonsteroidal antiinflammatory drug ( NSAIDS ) . If medication discontinue upon start Screening procedure plan regularly use trial , patient allow enter Study Use systemic corticosteroid ( oral , suppository , inject ) . Use inhale topical corticosteroid permit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>TT223</keyword>
</DOC>